Sunesis Pharmaceuticals, Inc. (NASDAQ:SNSS) – Research analysts at Cantor Fitzgerald issued their FY2018 earnings per share (EPS) estimates for Sunesis Pharmaceuticals in a research note issued to investors on Sunday. Cantor Fitzgerald analyst M. Goldstein expects that the biopharmaceutical company will earn ($1.08) per share for the year. Cantor Fitzgerald currently has a “Hold” rating and a $4.00 target price on the stock.
Sunesis Pharmaceuticals (NASDAQ:SNSS) last announced its quarterly earnings results on Thursday, March 8th. The biopharmaceutical company reported ($0.21) EPS for the quarter, beating analysts’ consensus estimates of ($0.29) by $0.08.
Sunesis Pharmaceuticals (NASDAQ SNSS) opened at $4.24 on Wednesday. Sunesis Pharmaceuticals has a one year low of $1.82 and a one year high of $7.69. The company has a market capitalization of $139.63, a P/E ratio of -2.79 and a beta of 1.39. The company has a debt-to-equity ratio of -0.34, a quick ratio of 1.84 and a current ratio of 1.84.
A number of hedge funds have recently modified their holdings of the business. BlackRock Inc. raised its position in Sunesis Pharmaceuticals by 9.5% during the fourth quarter. BlackRock Inc. now owns 130,573 shares of the biopharmaceutical company’s stock valued at $482,000 after purchasing an additional 11,351 shares during the period. Wells Fargo & Company MN raised its position in Sunesis Pharmaceuticals by 77.4% during the second quarter. Wells Fargo & Company MN now owns 41,851 shares of the biopharmaceutical company’s stock valued at $113,000 after purchasing an additional 18,254 shares during the period. Vanguard Group Inc. raised its position in Sunesis Pharmaceuticals by 4.1% during the second quarter. Vanguard Group Inc. now owns 605,759 shares of the biopharmaceutical company’s stock valued at $1,635,000 after purchasing an additional 23,819 shares during the period. Geode Capital Management LLC raised its position in Sunesis Pharmaceuticals by 105.2% during the fourth quarter. Geode Capital Management LLC now owns 125,489 shares of the biopharmaceutical company’s stock valued at $463,000 after purchasing an additional 64,343 shares during the period. Finally, Vatera Holdings LLC purchased a new stake in Sunesis Pharmaceuticals during the fourth quarter valued at approximately $673,000. Institutional investors and hedge funds own 53.20% of the company’s stock.
TRADEMARK VIOLATION WARNING: This article was originally reported by American Banking News and is the property of of American Banking News. If you are viewing this article on another website, it was stolen and republished in violation of U.S. & international trademark and copyright laws. The correct version of this article can be accessed at https://www.americanbankingnews.com/2018/03/14/research-analysts-issue-forecasts-for-sunesis-pharmaceuticals-inc-s-fy2018-earnings-snss.html.
Sunesis Pharmaceuticals Company Profile
Sunesis Pharmaceuticals, Inc is a biopharmaceutical company. The Company focuses on the development and commercialization of its pipeline of oncology therapeutics for the treatment of solid and hematologic cancers. The Company offers QINPREZO (vosaroxin), which is a product candidate for the treatment of acute myeloid leukemia (AML).
Receive News & Ratings for Sunesis Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sunesis Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.